About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Determining the mutation status of two genes, EGFR and KRAS, may enable health care professionals to identify which patients with non–small-cell lung cancer are likely to benefit from anti-epidermal growth factor receptor–tyrosine kinase inhibitor therapy rather than from chemotherapy.
Corey J. Langer, MD
An Economic Stimulus Plan for Missouri
Although many safety-net hospitals are facing reductions in Medicaid assistance, one facility has begun to transform its pharmacy program into a revenue producer based on expanded 340B access.
Of the many drugs that have been submitted to the FDA for treating obesity, only two are approved, and some that had been approved earlier have been removed from the market. The authors discuss the benefits and risks of several agents while noting the difficulty in obtaining approval for a safe weight-loss medication.
Carol A. Motycka, PharmD; Erin St. Onge, PharmD; and Shannon A. Miller, PharmD
Belimumab (Benlysta) for lupus and ipilimumab (Yervoy) for melanoma
Marvin M. Goldenberg, PhD, RPh, MS
High-dose isotretinoin (Accutane) for nodulocystic acne, briakinumab for psoriasis, biologics for psoriasis comorbidities, and therapies for nail fungal infections
Peter Sonnenreich, MA
11th European Congress on Osteoporosis and Osteoarthritis and International Liver Congress 2011 (46th European Association for the Study of the Liver)
Strontium ranelate (Protelos), zoledronic acid (Zometa), and denosumab (Prolia)
for bone health; boceprevir (Victrelis) and telaprevir for hepatitis C virus infection
Although potassium chloride is no longer stocked in patient-care units, this high alert drug can still pose a serious threat to patients.
Matthew Grissinger, RPh, FASCP
Senate Bill Might Help … or Not
A Senate bill, if passed, could help to alleviate the epidemic of widespread severe drug shortages, which cost hospital pharmacies at least $200 million annually.
FDA approvals, drug indications, and updates
A New Approach to Weight Loss in Obese Adults
Naltrexone SR/bupropion SR (Contrave) for weight loss
Tehane Ornellas, PharmD Candidate; and Benjamin Chavez, PharmD, BCPP